Sara Collesides, NP
Primary Care · Coxsackie, NYNPI 1528767084
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 71 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 18.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $578, 2.6 times the $226 reported in 2023.
Across 71 payments — averaging $18.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$245
- Pfizer$233
- Novo Nordisk$194
- Exact Sciences$147
- AstraZeneca$140
- Bayer$96
- plus $281 from 11 others
What the payments were for
- Food & beverage$1,335100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 12 | $245 |
| Pfizer | 12 | $233 |
| Novo Nordisk | 11 | $194 |
| Exact Sciences | 6 | $147 |
| AstraZeneca | 8 | $140 |
| Bayer | 5 | $96 |
| Abbott | 2 | $43 |
| Lilly USA, LLC | 3 | $41 |
| Axsome Therapeutics, Inc. | 2 | $38 |
| Amgen | 2 | $31 |
| Astellas Pharma US Inc | 2 | $28 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $23 |
| Dexcom, Inc. | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Tactile Systems Technology Inc | 1 | $15 |
| Sumitomo Pharma America, Inc. | 1 | $15 |
| Vertex | 1 | $14 |
How this compares
$1,335 in reported general payments places this provider in the 75th percentile of 239 primary care providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 34 | $32,357 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 18 | $16,391 |
| EliquisApixaban | 22 | $16,058 |
| Tresiba Flextouch U-100Insulin Degludec | 16 | $10,535 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 39 | $1,244 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 26 | $1,048 |
| Atorvastatin Calcium | 78 | $683 |
| Gabapentin | 43 | $670 |
| Ondansetron OdtOndansetron | 15 | $585 |
| Metoprolol Succinate | 34 | $567 |
| Omeprazole | 67 | $551 |
| Celecoxib | 19 | $423 |
| Levothyroxine Sodium | 51 | $407 |
| Rosuvastatin Calcium | 27 | $394 |
| Famotidine | 23 | $374 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $194 | $32,35734 claims |
| GSKTrelegy Ellipta | $245 | $16,39118 claims |
| PfizerEliquis | $233 | $16,05822 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 239 primary care providers in New York.
Other primary care in Coxsackie
- Dorothy KleinertNew York$27K
- Stephanie KhanForest Hills$16K
- Albert MarcanoJackson Heights$15K
- Elizabeth GattmanJamestown$10K
- Vanessa WangFlushing$10K
- Elizabeth SmithWaterloo$9K
- Eric RodriguezSyracuse$7K
- Natalie Sommerville-BrooksBrooklyn$6K
- Lisa PlanetaNew York$6K
- Pao-Ju TsengFlushing$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.